News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BG Medicine Announces Receipt of CE Mark for its Galectin-3 Blood Test



1/27/2010 11:38:52 AM

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, today announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES